drugset
drugset / Trial / NCT07026162

Oliceridine on Postoperative Nausea and Vomiting in Gynecological Laparoscopic Surgery

NCT07026162 ↗

Phase 4 Completed 96 enrolled YanYing Xiao
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this clinical trial is to evaluate the impact of the analgesic Oliceridine on postoperative nausea and vomiting (PONV) following gynecological laparoscopic surgery. It will also assess the safety profile of Oliceridine. The trial seeks to address the following key questions: Can Oliceridine reduce the incidence of postoperative nausea and vomiting (PONV) in gynecological laparoscopic surgery? Does the incidence of PONV differ between patients receiving Oliceridine and those receiving the commonly used analgesic sufentanil in gynecological laparoscopic surgery? Are there any opioid-related adverse reactions in gynecological laparoscopic surgery patients using Oliceridine? Participants will: Receive Oliceridine or sufentanil for anesthesia induction, maintenance, and postoperative pain management. Vital signs during surgery and the occurrence of postoperative nausea and vomiting will be recorded. Be followed up for at least 48 hours.

Timeline

Start
2025-07-21
Primary completion
2026-02-10
Completion
2026-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Oliceridine Other / unclassified 0.4 mg/kg Intravenous
Subject Sufentanil Other / unclassified 2 ug/kg Intravenous

Indications

No indication recorded.